Johnson & Johnson (JNJ)

148.00
1.66 1.11
NYSE
Prev Close 149.66
Open 148.54
Day Low/High 147.53 / 149.19
52 Wk Low/High 109.16 / 157.00
Volume 5.15M
Exchange NYSE
Shares Outstanding 2632.82B
Market Cap 386.95B
P/E Ratio 25.83
Div & Yield N.A. (N.A)
Johnson & Johnson Is Pulling Back to Retest its Breakout Zone

Johnson & Johnson Is Pulling Back to Retest its Breakout Zone

The broad market may be soft for another week but if I find more stocks in a similar position as JNJ I won't see a reason to join the bear camp.

Sell Signals, 'Operation Warp Speed,' Trading Notes

Sell Signals, 'Operation Warp Speed,' Trading Notes

Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.

Jim Cramer: Let the Froth Wash Out

Jim Cramer: Let the Froth Wash Out

Let's look at the stocks that will get crushed and that you can't touch right now.

The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance

The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance

I have always liked the aggressive management.

Are You a Trader, Investor, or Opportunist?

Are You a Trader, Investor, or Opportunist?

Don't pigeon hole yourself into a certain pattern of action when you see opportunities.

Want to Know Why I'm Not Selling Moderna?

Want to Know Why I'm Not Selling Moderna?

I'm staying long this name, and I'm staying long PFE and JNJ, and I'm staying long GILD and ABT. You know why? Because I'm optimistic.

This Chart Pattern Hints at a Bullish Future

This Chart Pattern Hints at a Bullish Future

The bullish reversal pattern is appearing not just in single names, but also in whole sectors.

Covering All Bases With Pfizer as It Aggressively Pursues a Covid-19 Vaccine

Covering All Bases With Pfizer as It Aggressively Pursues a Covid-19 Vaccine

PFE is collaborating with German drugmaker BioNTech in the effort to find a well tolerated, effective vaccine.

Earnings in Full Swing, Workplace Evolution, Fed Day

Earnings in Full Swing, Workplace Evolution, Fed Day

There was a mild increase in trading volume at the New York Stock Exchange, but it was a rotational shift.

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.

Johnson & Johnson Cut to Neutral at UBS

Jim Cramer: CEOs Better Come Out Jacked on Their Conference Calls

Jim Cramer: CEOs Better Come Out Jacked on Their Conference Calls

Stop apologizing, don't surrender to the gloom and tell your story with sympathy but with glory, and don't make us feel like it's a mistake to own shares in your company.

Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials

Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials

Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.

Jim Cramer: How to Stay Safe, Until Quick Testing for Covid-19 Is Available

Jim Cramer: How to Stay Safe, Until Quick Testing for Covid-19 Is Available

Welcome to the new era. Social distancing is not without risks, but it is as good as it gets.

Futures Pop, Gilead's Covid-19 Treatment, Trading My 'Virus Group'

Futures Pop, Gilead's Covid-19 Treatment, Trading My 'Virus Group'

The rise in equity futures pricing was born of optimism from the president's task force draft guideline on reopening parts of the U.S. economy and Gilead Sciences' somewhat positive results on its remdisivir anti-viral treatment.

My New Multi-Group Portfolio Strategy for Trading the Pandemic

My New Multi-Group Portfolio Strategy for Trading the Pandemic

How has my book evolved since the Fed and Treasury rode into town? Here's how.

5 Ways to Invest in Testing, Vaccines and Clinical Trials

5 Ways to Invest in Testing, Vaccines and Clinical Trials

These companies have the potential to help in battling the Covid-19 pandemic.

Jim Cramer: I Don't Think Covid-19 Is Invincible

Jim Cramer: I Don't Think Covid-19 Is Invincible

When it's beaten you will wish you own stocks, especially the stocks that are right now lethal to your portfolio.

Jim Cramer: Don't Mistake the Rally for Cheering

Jim Cramer: Don't Mistake the Rally for Cheering

There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.

These 3 Earnings Reports Illustrate What We Are Likely to See This Season

These 3 Earnings Reports Illustrate What We Are Likely to See This Season

Earnings season started with a mixed bag of reports.

Johnson & Johnson's Price Strength Is Ripping the Band-Aid Off This Rally

Johnson & Johnson's Price Strength Is Ripping the Band-Aid Off This Rally

Long-time investors in JNJ are probably not surprised how well the stock has responded in the past few weeks.

Johnson & Johnson Turns in Decent Results -- But That's Not Why I'm in the Stock

Johnson & Johnson Turns in Decent Results -- But That's Not Why I'm in the Stock

There are plenty of good reasons to invest in JNJ, but one resonates with me more than any other.

Inflationary Concerns, Banks Report Earnings, Netflix Soars: Market Recon

Inflationary Concerns, Banks Report Earnings, Netflix Soars: Market Recon

I did warn publicly back in another epoch that quantitative easing would lead toward increased consumer level inflation.

Will the Market Say, 'No Guidance, No Problem' This Earnings Season?

Will the Market Say, 'No Guidance, No Problem' This Earnings Season?

In view of the obvious economic issues that the market faces, it is interesting that sentiment is not more negative.

The Virus Remains in Control, Unrealistic V-Shaped Recovery, Trading 2 Stocks

The Virus Remains in Control, Unrealistic V-Shaped Recovery, Trading 2 Stocks

I do think the key to reopening this economy is one of greatly expanded testing for Covid-19, once a reliable treatment has made it past clinical testing, and into mass production.

Jim Cramer: Finding Any Stocks With No Hair?

Jim Cramer: Finding Any Stocks With No Hair?

After a company reports we all know what's wrong, it's immunized. And that's when you can buy.

Jim Cramer: Goodbye to a Horrid Quarter

Jim Cramer: Goodbye to a Horrid Quarter

Now that the service economy is pretty much stopped in its tracks, here are promising areas, including technology as manufacturing, to consider.

Good-Bye to March 2020, Retailmageddon, 32% Unemployment? Trading DocuSign

Good-Bye to March 2020, Retailmageddon, 32% Unemployment? Trading DocuSign

I don't think it would be too much of a stretch to imagine that too many investors, or citizens for that matter, will mind seeing March 2020 head on out of here.

Jim Cramer: Here's the Science Behind Our Rally

Jim Cramer: Here's the Science Behind Our Rally

While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.

Johnson & Johnson Is Ready to Rally After Reaching a Downside Price Target

Johnson & Johnson Is Ready to Rally After Reaching a Downside Price Target

While the short-term picture of JNJ suggests more risk is possible, the longer-term patterns are constructive.